Aethlon Medical Inc. develops therapeutic filtration devices to address infectious disease and cancer. The Medanta Independent Ethics Committee (MIEC) at the Medicity Institute (Medicity) in India recently approved a treatment program entitled: “Use of the Aethlon Hemopurifier® in Treating Chronic HCV Infection in Combination with Standard of Care (SOC) Drug Therapy.”

The Aethlon Hemopurifier is the first-of-its kind medical device that selectively targets the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system.

Aethlon said that one of the clinical goals of the Aethlon-Medicity study is to demonstrate that the Hemopurifier® can accelerate the benefit of HCV standard of care (SOC) drug regimens.

“We are grateful for this opportunity to show the pharmaceutical industry, infected patients, and shareholders that our Hemopurifier® can enhance the capabilities of drug regimens without adding additional drug toxicity and interaction risks,” Aethlon chairman and CEO Jim Joyce stated in the press release. “Beneficial outcomes will set the stage for the early commercialization of our technology and should recalibrate industry viewpoints on addressing infectious disease conditions.”

After conducting the clinical early treatment benefit, Aethlon said it plans to advance commercialization through the Medicity and other regional treatment centers in India. To execute this goal, Aethlon has inked a deal with GVK Biosciences (GVK BIO) to expand the opportunity for Aethlon to commercialize its Hemopurifier® treatment technology at three to five new clinical centers in India. GVK BIO is Asia’s leading discovery research and development organization.

Aethlon said the Hemopurifier offers the company opportunity in four significant markets: as a cancer treatment candidate to improve patient responsiveness to established cancer therapies by removing immunosuppressive exosomes from circulation; as a Hepatitis-C Virus (HCV) adjunct therapy to accelerate viral load reduction at the outset of standard of care drug regimens; as a potential therapeutic option for Human Immunodeficiency Virus (HIV) for infected individuals to manage disease progression once they become resistant to antiviral drug regimens; and for bioterror and pandemic threats, representing the most advanced broad-spectrum strategy to address untreatable bioterror and emerging pandemic threats.

For more information visit www.aethlonmedical.com